Mahamaya Lifesciences (BOM:544611) Total Receivables: ₹853 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544611 Mahamaya Lifesciences Ltd BOM:544611
16 GF Score
Price ₹166.45
! 4 Warning Signs
View Full Analysis

What is Mahamaya Lifesciences Total Receivables?

Mahamaya Lifesciences BOM:544611 16 Total Receivables is ₹853 Mil as of Mar. 2026. GuruFocus rates BOM:544611 with a GF Score™ of 16/100. The stock has 4 warning signs investors should review.

Mahamaya Lifesciences's Total Receivables for the quarter that ended in Mar. 2026 was ₹853 Mil.

Mahamaya Lifesciences Total Receivables Related Terms

Mahamaya Lifesciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Mahamaya Lifesciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mahamaya Lifesciences Total Receivables Chart

Mahamaya Lifesciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
91.23 95.86 283.98 486.83 852.55

Mahamaya Lifesciences Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Mar26
Total Receivables Get a 7-Day Free Trial 95.86 283.98 318.91 486.83 852.55
BOM:544611
16GF Score
Mahamaya Lifesciences Ltd BOM:544611
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mahamaya Lifesciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹853 Mil mean?
Mahamaya Lifesciences (BOM:544611) has a Total Receivables of ₹853 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Mahamaya Lifesciences and its competitors.
Is Mahamaya Lifesciences' Total Receivables too high?
Mahamaya Lifesciences' current Total Receivables is ₹853 Mil. Overall, Mahamaya Lifesciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Mahamaya Lifesciences' Total Receivables compare to CTVA and CF?
Mahamaya Lifesciences' Total Receivables of ₹853 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for an Agriculture company?
A good Total Receivables depends on the Agriculture industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Mahamaya Lifesciences and its competitors. Mahamaya Lifesciences's current Total Receivables is ₹853 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mahamaya Lifesciences stock overvalued right now?
Mahamaya Lifesciences (BOM:544611) has a current Total Receivables of ₹853 Mil. The current Total Receivables is ₹853 Mil. Mahamaya Lifesciences' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Mahamaya Lifesciences (BOM:544611), the current Total Receivables is ₹853 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mahamaya Lifesciences Business Description

Address Sohna Road, Sector-49, Unit No. 369, 370, 370A & 370B, 3rd Floor, Prime Tower-B1, Spaze ITech Park, Gurugram, HR, IND, 122018
Mahamaya Lifesciences Ltd specializes in the manufacturing of pesticide formulations and supplies bulk formulations catering to both Indian agrochemical companies as well as multinational corporations (MNCs). The company's offerings include Insecticides, Herbicides, and Fungicides. Geographically, it serves multiple Indian states including Punjab, Haryana, Rajasthan, and Uttar Pradesh, and internationally serves countries like the Dominican Republic, Turkey, Egypt, and the UAE. The company generates revenue from the sale of its pesticide formulations.
16GF Score

Get the complete analysis for BOM:544611

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹166.45
Price